Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …

Background Radiomic features may quantify characteristics present in medical imaging.
However, the lack of standardized definitions and validated reference values have …

Background Improved markers of prognosis are needed to stratify patients with early-stage
colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to …

Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic
process. This family comprises proapoptotic and prosurvival proteins, and shifting the …

A set of electrostatically charged, fluorescent, and superparamagnetic nanoprobes was
developed for targeting cancer cells without using any molecular biomarkers. The surface …

TP53, a critical tumour suppressor gene, is mutated in over half of all cancers resulting in
mutant-p53 protein accumulation and poor patient survival. Therapeutic strategies to target …

The selection of circulating tumor cells (CTCs) directly from blood as a real-time liquid
biopsy has received increasing attention over the past ten years, and further analysis of …

Aptamers are single-stranded nucleic acids that selectively bind to target molecules. Most
aptamers are obtained through a combinatorial biology technique called SELEX. Since …

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and
personalized medicine. However, investigators are now elucidating intratumor heterogeneity …